Liposomal cancer chemotherapy: Current clinical applications and future prospects

Expert Opinion on Investigational Drugs

Volumn 10, Issue 6, 2001, Pages 1045-1061

  Harrington, K J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Biodistribution; Chemoradiotherapy; Cytotoxic chemotherapy; Efficacy; Immunoliposome; Liposome; Pegylated; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHOLESTEROL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DOXORUBICIN; DRUG VEHICLE; EVACET; FLUOROURACIL; IDOXURIDINE; LIPOSOME; PENTETATE TECHNETIUM TC 99M; PHOSPHATIDYLCHOLINE; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PLATINUM DERIVATIVE; RADIOSENSITIZING AGENT; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AIDS RELATED COMPLEX; ALOPECIA; BONE MARROW SUPPRESSION; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DEATH; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; FEVER; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEAD AND NECK CANCER; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; ISOTOPE LABELING; KAPOSI SARCOMA; KIDNEY DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG CANCER; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CLEARANCE; PLEURA MESOTHELIOMA; REVIEW; SARCOMA;

ANTHRACYCLINES; CLINICAL TRIALS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 0034993103     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.6.1045     Document Type: Review

References (161)

1. Diffusion of univalent ions across the lamellae of swollen phospholipids
2. Drug-carrier potential of liposomes in cancer chemotherapy
3. The carrier potential of liposomes in biology and medicine (first of two parts)
4. The carrier potential of liposomes in biology and medicine (second of two parts)
5. Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development
6. In-111-labelled liposomes: Dosimetry and tumour depiction
7. Successful imaging of human cancer with Indium-111-labelled phospholipid vesicles
8. Preliminary report: Imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes
9. Indium-111-labelled liposomes: Dosimetry and tumour detection in patients with cancer
10. Liposomal distribution in malignant glioma: Possibilities for therapy
11. Distribution of daunorubicin and daunorubicinol in human glioma tumours after administration of liposomal daunorubicin
12. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
13. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumour localisation, and safety in patients with AIDS-related Kaposi's sarcoma
14. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
15. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
16. High intratumoural accumulation of stealth liposomal doxorubicin in sarcomas - Rationale for combination with radiotherapy
17. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours
18. Effective targeting of solid tumours in patients with locally advanced cancers by radiolabelled pegylated liposomes
19. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non small-cell lung cancer patients
20. Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)
21. Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomised trial of metastatic breast carcinoma (MBC)
22. Phase III study of liposome-encapsulated doxorubicin (TLC D-99) versus doxorubicin (DOX) in combination with cyclophosphamide (CPA) in patients with metastatic breast cancer (MBC)
23. Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (Dox) in patients with metastatic breast carcinoma (MBC)
24. AIDS-related Kaposi's sarcoma: A Phase II study of liposomal doxorubicin
25. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
26. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
27. Reduced cardiotoxicity of liposome-encapsulated doxorubicin (TLC D-99) compared to free doxorubicin in first-line therapy of metastatic breast cancer in patients at increased risk for anthracycline-induced cardiac toxicity
28. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin
29. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma
30. Liposomal daunorubicin in advanced Kaposi's sarcoma: A Phase II study
31. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma
32. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma
33. Randomised Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma
34. Phase I study of liposomal daunorubicin in patients with acute leukemia
35. Phase I/II trial of liposomal daunorubicin in malignant mesothelioma
36. Phase II studies with DaunoXome in patients with non-resectable hepatocellular carcinoma: Clinical and pharmacokinetic outcomes
37. Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis
38. Phase I clinical and pharmacology study of liposome-entrapped cis-bis-neodecanoato trans-R,R-1,2 diaminocyclohexane platinum (II)
39. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) and cisplatin given i.v. and i.p. in the rat
40. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions
41. Phase II study of liposome-entrapped cisplatin-analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma
42. Phase I study of liposomal vincristine
43. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Eearly results of an ongoing Phase II trial
44. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma
45. Liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma
46. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma
47. Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS
48. Liposomal entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
49. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma
50. Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
51. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomised Phase III clinical trial
52. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma
53. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
54. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
55. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
56. Interim analysis of a Phase III randomized trial of Caelyx/Doxil (D) versus Topotecan (T) in the treatment of patients with relapsed ovarian cancer
57. Phase II study of liposomal doxorubicin in advanced gynecologic cancers
58. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicentre Phase II trial
59. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
60. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
61. Phase II study of pegylated liposomal doxorubicin (Caelyx™) in patients with inoperable, locally advanced squamous cell cancer of the head and neck
62. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
63. A randomised Phase II trial of Caelyx®/Doxil® versus doxorubicin in advanced or metastatic soft tissue sarcomas (STS) - An EORTC Soft Tissue and Bone Sarcoma (STBSG) trial
64. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A Phase II study of the Italian Sarcoma Group (ISG)
65. Pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HCC)
66. Phase II study of Caelyx® (Doxil®; doxorubicin HCl pegylated liposomal) in the treatment of small cell lung cancer (SCLC)
67. Activity of pegylated liposomal doxorubicin (Caelyx) in advanced transitional cell carcinoma (TCC)
68. Liposomal doxorubicin (Caelyx) in the treatment of recurrent high-grade glioma - A Phase II/III study
69. A Phase II trial of liposomal doxorubicin (Doxil®) in the treatment of advanced renal cell cancer: A Hoosier Oncology Group (HOG) study
70. Phase II trial of Caelyx™ (Liposomal Doxorubicin, (Doxil™) in the treatment of advanced pancreatic cancer
71. Pegylated liposomal doxorubicin (PEG-LD) as second line treatment of advanced non-small cell carcinoma (NSCLC) after platinum-based therapy: A randomised Phase II trial
72. Weekly pegylated liposomal doxorubicin is extremely well tolerated as second line chemotherapy
73. Phase II trial of Doxil in advanced soft tissue sarcomas (STS)
74. Early results of pegylated liposomal doxorubicin (Doxil®) in refractory sarcoma
75. A Phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
76. Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer
77. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: A report on ten patients with follow-up
78. Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel
79. Phase II trial to evaluate the safety and tolerability of Caelyx® in combination with paclitaxel in the treatment of metastatic cancer
80. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HC1 liposome injection (Doxil®) plus paclitaxel (DT) in metastatic breast cancer
81. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer
82. Phase I trial and interaction pharmacokinetics of pegylated-liposomal doxorubicin (Caelyx; Doxil) and weekly Taxol
83. Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (PTS) with advanced breast cancer (ABC)
84. Doxil plus cisplatin: Combined results of two Phase I studies
85. Phase I trial of Doxil® plus vinorelbine (VNB) in patients (PTS) with advanced malignancies
86. A Phase I/II study of Doxil and vinorelbine in metastatic breast cancer patients
87. Doxil® and oral cyclophosphamide as first-linetherapy for patients with metastatic breast cancer (MBC): Preliminary results of a pilot trial
88. A Phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer
89. A Phase I study of liposomal doxorubicin and temozolomide in patients with advanced cancer
90. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: Preliminary data
91. Lack of vesicant injury following extravasation of liposomal doxorubicin
92. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin
93. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
94. 2
95. Strategies for reduction of anthracycline cardiac toxicity
96. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy
97. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model
98. Treatment of palmar-plantar erythrodysaesthesia with pyridoxine or ergotamine: Effect on efficacy of Doxil in Lewis lung carcinoma
99. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
100. Amifostine reduces severity and incidence of Doxil-induced palmar/plantar erythrodysesthesis in rats but does not reduce Doxil antitumour efficacy or alter pharmacokinetics in mice
101. A Phase I study of liposome-formulated cisplatin (SPI-77®) given every 3 weeks in patients with advanced cancer
102. Phase I trial of SPI-077 plus paclitaxel in patients with refractory non-small cell lung cancer (NSCLC)
103. Phase I/II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer
104. Anticancer effect of 9-nitrocamprothecin liposome aerosol on human cancer xenografts in nude mice
105. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice
106. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models
107. Improved treatment for cervical cancer - Concurrent chemotherapy and radiotherapy
108. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)
109. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data
110. Stealth liposome encapsulated doxorubicin (SLED) and iododeoxyuridine (SLIUDR) as radiation sensitisers in head and neck squamous cell cancer xenograft tumours (HNSCCXT)
111. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumour xenograft model
112. Single-fraction irradiation has no effect on uptake of radiolabelled pegylated liposomes in a tumor xenograft model
113. The effect of irradiation on the biodistribution of radiolabelled pegylated liposomes in nude mice
114. Immunoliposomes for the targeted delivery of antitumor drugs
115. Interactions of immunoliposomes with target cells
116. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies
117. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo
118. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor
119. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs
120. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide
121. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells
122. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells
123. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model
124. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo
125. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo
126. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages
127. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes
128. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumours in vivo
129. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma
130. Immunospecific targeting of cytosine arabinonucleoside-containing liposomes to the idiotype on the surface of a murine B-cell tumor in vitro and in vivo
131. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue
132. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
133. Development of anti-p185HER2 immunoliposomes for cancer therapy
134. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies
135. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice
136. Liposomes-based therapy of human ovarian cancer: Parameters determining potency of negatively charged and antibody-targeted liposomes
137. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice
138. Genetics of multidrug resistance
139. P-glycoprotein, multidrug resistance and tumour progression
140. Multidrug resistance: Clinical relevance in solid tumours and strategies for circumvention
141. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene
142. Expression of a multidrug resistance gene in human cancers
143. MDR1 gene expression in solid tumours
144. Mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy
145. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma
146. MDR1 gene expression and prognostic factors in primary breast carcinomas
147. MDR1 gene expression and its clinical relevance in primary gastric carcinomas
148. Prognostic relevance of P-glycoprotein expression in breast cancer
149. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin
150. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells
151. Effect of liposomes on P-glycoprotein function in multidrug resistant cells
152. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes
153. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance
154. Effect of mitoxantrone liposomes on multidrug-resistant breast cancer cells
155. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells
156. In vitro sensitivity to the liposomal preparation, DaunoXome in CLL
157. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors
158. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin
159. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma
160. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma
161. Pharmacokinetic behaviour of vincristine sulfate following administration of vincristine sulfate liposome injection